The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gorny, M. K.
Right arrow Articles by Zolla-Pazner, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gorny, M. K.
Right arrow Articles by Zolla-Pazner, S.

The Journal of Immunology, Vol 150, Issue 2 635-643, Copyright © 1993 by American Association of Immunologists

ARTICLES

Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120

MK Gorny, JY Xu, S Karwowska, A Buchbinder and S Zolla-Pazner
Department of Pathology, NYU Medical School, NY 10016.

HIV infection induces antibodies that mediate neutralization of cell- free virus and may protect against viral infection. Neutralizing human mAb that bind to the third hypervariable domain (V3) of gp120 have been generated from PBL of HIV-seropositive subjects. Twelve such mAb recognize 9 different epitopes spanning an 11 amino acid stretch at the tip of the V3MN loop. The epitopes of an additional two mAb have not been precisely determined but occur within a 15-mer peptide around the tip of the V3 loop. Eleven of 13 mAb are reactive with at least one other V3 peptide besides MN, indicating that cross-reactivity is a common phenomenon amongst anti-V3 antibodies. All the mAb achieved 50% neutralization of HIVMN at antibody concentrations of 12 to 4700 ng/ml. Two mAb, which recognized epitopes at the top of the V3 loop, GPGR and GRAF, neutralized strains as divergent as MN and IIIB. The affinities of all mAb tested were shown to be substantially higher for the rgp120 than for a 23-mer peptide from the V3 loop of the homologous strain. A significant inverse correlation was demonstrated between affinities and the 50% neutralizing doses for HIVMN.


This article has been cited by other articles:


Home page
 J. Virol.Home page
A. Forsman, E. Beirnaert, M. M. I. Aasa-Chapman, B. Hoorelbeke, K. Hijazi, W. Koh, V. Tack, A. Szynol, C. Kelly, A. McKnight, et al.
Llama Antibody Fragments with Cross-Subtype Human Immunodeficiency Virus Type 1 (HIV-1)-Neutralizing Properties and High Affinity for HIV-1 gp120
J. Virol., December 15, 2008; 82(24): 12069 - 12081.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Stevceva, V. Yoon, A. Carville, B. Pacheco, M. Santosuosso, B. Korioth-Schmitz, K. Mansfield, and M. C. Poznansky
The Efficacy of T Cell-Mediated Immune Responses Is Reduced by the Envelope Protein of the Chimeric HIV-1/SIV-KB9 Virus In Vivo
J. Immunol., October 15, 2008; 181(8): 5510 - 5521.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Li, B. Cleveland, I. Klots, B. Travis, B. A. Richardson, D. Anderson, D. Montefiori, P. Polacino, and S.-L. Hu
Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses
J. Virol., January 15, 2008; 82(2): 638 - 651.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. B. Patel, N. G. Hoffman, and R. Swanstrom
Subtype-Specific Conformational Differences within the V3 Region of Subtype B and Subtype C Human Immunodeficiency Virus Type 1 Env Proteins
J. Virol., January 15, 2008; 82(2): 903 - 916.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Z. Kraft, N. R. Derby, R. A. McCaffrey, R. Niec, W. M. Blay, N. L. Haigwood, E. Moysi, C. J. Saunders, T. Wrin, C. J. Petropoulos, et al.
Macaques Infected with a CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV) Develop Broadly Reactive Anti-HIV Neutralizing Antibodies
J. Virol., June 15, 2007; 81(12): 6402 - 6411.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. K. Dhillon, H. Donners, R. Pantophlet, W. E. Johnson, J. M. Decker, G. M. Shaw, F.-H. Lee, D. D. Richman, R. W. Doms, G. Vanham, et al.
Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors
J. Virol., June 15, 2007; 81(12): 6548 - 6562.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. R. Derby, Z. Kraft, E. Kan, E. T. Crooks, S. W. Barnett, I. K. Srivastava, J. M. Binley, and L. Stamatatos
Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection.
J. Virol., September 1, 2006; 80(17): 8745 - 8762.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. K. Gorny, C. Williams, B. Volsky, K. Revesz, X.-H. Wang, S. Burda, T. Kimura, F. A. J. Konings, A. Nadas, C. A. Anyangwe, et al.
Cross-Clade Neutralizing Activity of Human Anti-V3 Monoclonal Antibodies Derived from the Cells of Individuals Infected with Non-B Clades of Human Immunodeficiency Virus Type 1
J. Virol., July 15, 2006; 80(14): 6865 - 6872.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Eda, M. Takizawa, T. Murakami, H. Maeda, K. Kimachi, H. Yonemura, S. Koyanagi, K. Shiosaki, H. Higuchi, K. Makizumi, et al.
Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif.
J. Virol., June 1, 2006; 80(11): 5552 - 5562.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Eda, T. Murakami, Y. Ami, T. Nakasone, M. Takizawa, K. Someya, M. Kaizu, Y. Izumi, N. Yoshino, S. Matsushita, et al.
Anti-V3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian/Human Immunodeficiency Virus Infection.
J. Virol., June 1, 2006; 80(11): 5563 - 5570.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. L. Stanfield, M. K. Gorny, S. Zolla-Pazner, and I. A. Wilson
Crystal Structures of Human Immunodeficiency Virus Type 1 (HIV-1) Neutralizing Antibody 2219 in Complex with Three Different V3 Peptides Reveal a New Binding Mode for HIV-1 Cross-Reactivity.
J. Virol., June 1, 2006; 80(12): 6093 - 6105.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
V. Holl, M. Peressin, S. Schmidt, T. Decoville, S. Zolla-Pazner, A.-M. Aubertin, and C. Moog
Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation
Blood, June 1, 2006; 107(11): 4466 - 4474.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. Yuste, H. B. Sanford, J. Carmody, J. Bixby, S. Little, M. B. Zwick, T. Greenough, D. R. Burton, D. D. Richman, R. C. Desrosiers, et al.
Simian Immunodeficiency Virus Engrafted with Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Epitopes: Replication, Neutralization, and Survey of HIV-1-Positive Plasma
J. Virol., March 15, 2006; 80(6): 3030 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. de Parseval, M. D. Bobardt, A. Chatterji, U. Chatterji, J. H. Elder, G. David, S. Zolla-Pazner, M. Farzan, T.-H. Lee, and P. A. Gallay
A Highly Conserved Arginine in gp120 Governs HIV-1 Binding to Both Syndecans and CCR5 via Sulfated Motifs
J. Biol. Chem., November 25, 2005; 280(47): 39493 - 39504.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. J. Saunders, R. A. McCaffrey, I. Zharkikh, Z. Kraft, S. E. Malenbaum, B. Burke, C. Cheng-Mayer, and L. Stamatatos
The V1, V2, and V3 Regions of the Human Immunodeficiency Virus Type 1 Envelope Differentially Affect the Viral Phenotype in an Isolate-Dependent Manner
J. Virol., July 15, 2005; 79(14): 9069 - 9080.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. Martin-Garcia, S. Cocklin, I. M. Chaiken, and F. Gonzalez-Scarano
Interaction with CD4 and Antibodies to CD4-Induced Epitopes of the Envelope gp120 from a Microglial Cell-Adapted Human Immunodeficiency Virus Type 1 Isolate
J. Virol., June 1, 2005; 79(11): 6703 - 6713.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. K. Gorny, L. Stamatatos, B. Volsky, K. Revesz, C. Williams, X.-H. Wang, S. Cohen, R. Staudinger, and S. Zolla-Pazner
Identification of a New Quaternary Neutralizing Epitope on Human Immunodeficiency Virus Type 1 Virus Particles
J. Virol., April 15, 2005; 79(8): 5232 - 5237.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. Krachmarov, A. Pinter, W. J. Honnen, M. K. Gorny, P. N. Nyambi, S. Zolla-Pazner, and S. C. Kayman
Antibodies That Are Cross-Reactive for Human Immunodeficiency Virus Type 1 Clade A and Clade B V3 Domains Are Common in Patient Sera from Cameroon, but Their Neutralization Activity Is Usually Restricted by Epitope Masking
J. Virol., January 15, 2005; 79(2): 780 - 790.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
X. Yang, V. Tomov, S. Kurteva, L. Wang, X. Ren, M. K. Gorny, S. Zolla-Pazner, and J. Sodroski
Characterization of the Outer Domain of the gp120 Glycoprotein from Human Immunodeficiency Virus Type 1
J. Virol., December 1, 2004; 78(23): 12975 - 12986.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. M. Binley, T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, et al.
Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies
J. Virol., December 1, 2004; 78(23): 13232 - 13252.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
P. C. Chien Jr., S. Cohen, M. Tuen, J. Arthos, P.-d. Chen, S. Patel, and C. E. Hioe
Human Immunodeficiency Virus Type 1 Evades T-Helper Responses by Exploiting Antibodies That Suppress Antigen Processing
J. Virol., July 15, 2004; 78(14): 7645 - 7652.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. A. McCaffrey, C. Saunders, M. Hensel, and L. Stamatatos
N-Linked Glycosylation of the V3 Loop and the Immunologically Silent Face of gp120 Protects Human Immunodeficiency Virus Type 1 SF162 from Neutralization by Anti-gp120 and Anti-gp41 Antibodies
J. Virol., April 1, 2004; 78(7): 3279 - 3295.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. K. Gorny, K. Revesz, C. Williams, B. Volsky, M. K. Louder, C. A. Anyangwe, C. Krachmarov, S. C. Kayman, A. Pinter, A. Nadas, et al.
The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope
J. Virol., March 1, 2004; 78(5): 2394 - 2404.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. Pantophlet, I. A. Wilson, and D. R. Burton
Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design
J. Virol., May 15, 2003; 77(10): 5889 - 5901.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
P. Poignard, M. Moulard, E. Golez, V. Vivona, M. Franti, S. Venturini, M. Wang, P. W. H. I. Parren, and D. R. Burton
Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies
J. Virol., December 6, 2002; 77(1): 353 - 365.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. K. Gorny, C. Williams, B. Volsky, K. Revesz, S. Cohen, V. R. Polonis, W. J. Honnen, S. C. Kayman, C. Krachmarov, A. Pinter, et al.
Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades
J. Virol., August 12, 2002; 76(18): 9035 - 9045.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y. He, W. J. Honnen, C. P. Krachmarov, M. Burkhart, S. C. Kayman, J. Corvalan, and A. Pinter
Efficient Isolation of Novel Human Monoclonal Antibodies with Neutralizing Activity Against HIV-1 from Transgenic Mice Expressing Human Ig Loci
J. Immunol., July 1, 2002; 169(1): 595 - 605.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. G. Edwards, S. Wyss, J. D. Reeves, S. Zolla-Pazner, J. A. Hoxie, R. W. Doms, and F. Baribaud
Truncation of the Cytoplasmic Domain Induces Exposure of Conserved Regions in the Ectodomain of Human Immunodeficiency Virus Type 1 Envelope Protein
J. Virol., February 22, 2002; 76(6): 2683 - 2691.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
O. Scharf, H. Golding, L. R. King, N. Eller, D. Frazier, B. Golding, and D. E. Scott
Immunoglobulin G3 from Polyclonal Human Immunodeficiency Virus (HIV) Immune Globulin Is More Potent than Other Subclasses in Neutralizing HIV Type 1
J. Virol., July 15, 2001; 75(14): 6558 - 6565.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
P. N. Nyambi, A. Nádas, H. A. Mbah, S. Burda, C. Williams, M. K. Gorny, and S. Zolla-Pazner
Immunoreactivity of Intact Virions of Human Immunodeficiency Virus Type 1 (HIV-1) Reveals the Existence of Fewer HIV-1 Immunotypes than Genotypes
J. Virol., November 15, 2000; 74(22): 10670 - 10680.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
F. Verrier, S. Burda, R. Belshe, A.-M. Duliege, J.-L. Excler, M. Klein, and S. Zolla-Pazner
A Human Immunodeficiency Virus Prime-Boost Immunization Regimen in Humans Induces Antibodies That Show Interclade Cross-Reactivity and Neutralize Several X4-, R5-, and Dualtropic Clade B and C Primary Isolates
J. Virol., November 1, 2000; 74(21): 10025 - 10033.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
P. N. Nyambi, H. A. Mbah, S. Burda, C. Williams, M. K. Gorny, A. Nádas, and S. Zolla-Pazner
Conserved and Exposed Epitopes on Intact, Native, Primary Human Immunodeficiency Virus Type 1 Virions of Group M
J. Virol., August 1, 2000; 74(15): 7096 - 7107.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
S. Zolla-Pazner, M. K. Gorny, P. N. Nyambi, T. C. VanCott, and A. Nádas
Immunotyping of Human Immunodeficiency Virus Type 1 (HIV): an Approach to Immunologic Classification of HIV
J. Virol., May 1, 1999; 73(5): 4042 - 4051.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
P. N. Nyambi, M. K. Gorny, L. Bastiani, G. van der Groen, C. Williams, and S. Zolla-Pazner
Mapping of Epitopes Exposed on Intact Human Immunodeficiency Virus Type 1 (HIV-1) Virions: a New Strategy for Studying the Immunologic Relatedness of HIV-1
J. Virol., November 1, 1998; 72(11): 9384 - 9391.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
L. Stamatatos and C. Cheng-Mayer
An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades
J. Virol., October 1, 1998; 72(10): 7840 - 7845.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. Cecilia, V. N. KewalRamani, J. O'Leary, B. Volsky, P. Nyambi, S. Burda, S. Xu, D. R. Littman, and S. Zolla-Pazner
Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage
J. Virol., September 1, 1998; 72(9): 6988 - 6996.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. Li, H. Katinger, M. R. Posner, L. Cavacini, S. Zolla-Pazner, M. K. Gorny, J. Sodroski, T.-C. Chou, T. W. Baba, and R. M. Ruprecht
Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins
J. Virol., April 1, 1998; 72(4): 3235 - 3240.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.